What RevOps Maturity Level Is Your Life Sciences Company Actually At? (And What to Do Next)
Most growth-stage pharma and biotech companies think they have a forecasting problem. What they actually have is a maturity problem, and those require very different fixes.
If your commercial team is running on disconnected spreadsheets, reacting to pipeline surprises in the week before close, and still debating who owns the handoff between marketing and sales, you are not dealing with a tooling gap. You are operating at RevOps maturity level 1 or 2. The good news: that is fixable. The better news: knowing exactly where you sit gives you a prioritized roadmap instead of an endless list of “we should probably also fix…” items.
Why Most Life Sciences Commercial Teams Don’t Know Their Maturity Level
Here is the pattern I see consistently: a biotech company raises a Series B, hires a Head of Commercial Ops or VP of RevOps, and that person inherits a CRM that three sales reps have been updating inconsistently since launch, a marketing automation platform no one has cleaned since implementation, and a forecasting process that lives in the CFO’s Excel model. The team is capable. The intent is good. But the infrastructure was never designed to scale.
The problem is not that the team lacks ambition, it is that they have no baseline. Without a framework to assess where they actually stand, every quarter becomes reactive. They fix the loudest problem, ship a new dashboard, clean up a few opportunity stages, and move on. Six months later, the same issues resurface in a slightly different shape. A RevOps maturity model solves this by giving commercial leaders a shared language, an honest diagnostic, and a sequence that builds on itself rather than looping.
The Four Levels of RevOps Maturity (For Life Sciences Commercial Teams)
Here is how I frame maturity for growth-stage life sciences companies specifically. These are not abstract categories, they map to real operational conditions.
Level 1, Fragmented. Data lives in silos. Your CRM is partially populated at best. Marketing runs their funnel metrics separately from sales. Forecasting is largely intuitive. Handoffs between marketing, sales, and commercial ops are undefined or ad hoc. There is no pipeline governance framework, stages mean different things to different reps. Revenue intelligence dashboards, if they exist, pull from sources no one fully trusts.
At this level, the priority is not optimization. It is foundation-setting: standardizing opportunity stages, establishing lead status governance, and completing a RevOps workflow audit to understand what your data actually reflects versus what leadership thinks it reflects.
Level 2, Reactive. The CRM is being used, but inconsistently. You have some reporting in place, but forecasts still shift dramatically in the final weeks of a quarter. Marketing and sales share pipeline data, but pipeline leakage analysis is not a standard practice, you only investigate deals after they are lost. Handoffs exist on paper but break down in execution. This is where shadow CRM remediation becomes critical: the unofficial spreadsheets and personal pipelines that reps maintain outside the system are a symptom of trust issues, not laziness.
Most growth-stage pharma and biotech commercial teams land here. They have invested in tools, but not in process architecture. Fixing level 2 means rebuilding forecast confidence, establishing marketing-to-sales funnel alignment with agreed-upon definitions, and introducing pipeline governance at the deal level.
Level 3, Structured. At this level, the team runs a documented GTM process with clear ownership at every stage. Opportunity stage consistency is enforced through CRM validation rules, not just manager conversations. Forecasting is data-driven and reviewed weekly with confidence categories. Marketing, sales, and commercial ops operate from a shared revenue intelligence dashboard. Account-level revenue visibility exists, which means leadership can see coverage gaps and prioritize accordingly. Territory coverage optimization is possible because the underlying data is clean enough to act on.
Moving from level 2 to level 3 is the hardest jump, it requires both technical remediation and behavior change. But it is also where the ROI becomes visible: shorter sales cycles, faster sales onboarding acceleration, and forecast accuracy that actually earns leadership trust.
Level 4, Predictive. Pipeline efficiency is tied directly to revenue targets. The team runs ongoing pipeline leakage analysis and knows where deals stall by stage, segment, and rep. AI-assisted forecasting surfaces deal risk before it becomes a surprise. GTM process transparency means every function, including finance and leadership, is working from the same version of reality. RevOps is not a support function at this level; it is a strategic asset. Full pipeline visibility enables resource allocation, headcount planning, and board reporting that leadership can stand behind.
Few growth-stage life sciences companies operate here. But the path is clear, and level 3 is the realistic near-term goal for most teams.
Why Life Sciences Commercial Teams Face Unique Maturity Barriers
The standard RevOps playbook assumes a relatively clean commercial environment: defined products, consistent pricing, a sales cycle that follows a predictable arc. Life sciences commercial teams operate under different conditions.
Launch timelines shift based on regulatory milestones. Commercial teams often scale rapidly after approval, which means the CRM infrastructure built for a ten-person launch team suddenly needs to support fifty reps across multiple territories and indications. Compliance requirements constrain what can be tracked and how it is stored. Medical, legal, and regulatory review processes introduce approval friction that most GTM alignment frameworks do not account for. Add in distributor relationships, specialty pharmacy channels, and the complexity of HCP targeting, and you have a commercial motion that requires a RevOps approach purpose-built for life sciences, not a SaaS playbook retrofitted to fit.
This is why GTM alignment for biotech and medtech cannot be copy-pasted from a tech company’s RevOps handbook. The diagnostic has to account for these constraints, and the maturity roadmap has to sequence fixes in a way that respects the operational reality of a regulated, resource-constrained, growth-stage environment.
Where to Go From Here
If you read through the four levels and recognized your team somewhere in the first two, that is actually useful information. It tells you that the problem is structural, not personal, and that a pipeline audit for life sciences focused on data quality, process architecture, and GTM process transparency will surface more actionable insights than another round of tool evaluations.
The goal is not to reach level 4 by next quarter. The goal is to know exactly what level you are at, understand what is blocking the next step, and build a sequenced roadmap that moves you forward without burning the team on fixes that do not compound. At Vida Solutions, that diagnostic work is where most engagements begin, because knowing your starting point is the only way to know whether you are making real progress.